CAH$206.335
Chart
Performance
Key Stats
AI CAH Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyCardinal Health demonstrates strong fundamental performance, particularly in revenue and net income growth. Thematic tailwinds in healthcare services are positive, but current technical indicators suggest a period of consolidation might be near.
Thematic
Cardinal Health benefits from consistent demand in healthcare services and distribution. Trends in efficiency and supply chain management within healthcare are positive for the company.
Fundamental
Cardinal Health shows robust revenue growth and improving profitability. Its balance sheet is solid with manageable debt, and it generates significant free cash flow.
Technical
The stock is in a clear uptrend over the medium to long term, but short-term indicators suggest a potential for a pause or slight retracement. Key moving averages are crossed positively, but oscillators show mixed signals.
| Factor | Score |
|---|---|
| Healthcare Services Demand | 80 |
| Supply Chain Efficiency | 75 |
| Aging Population | 70 |
| Regulatory Landscape | 50 |
| Competition | 60 |
| Factor | Score |
|---|---|
| Valuation | 60 |
| Profitability | 50 |
| Growth | 80 |
| Balance Sheet Health | 45 |
| Cash Flow | 85 |
| Factor | Score |
|---|---|
| Trend Analysis | 70 |
| Momentum | 50 |
| Support & Resistance | 75 |
| Volume | 70 |
| Short-term Oscillators | 70 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Consistent EPS Beat
Cardinal Health (CAH) has a strong track record of beating earnings per share (EPS) estimates, with positive surprises in 11 out of the last 12 quarters. The most recent quarter (2025Q1) showed an EPS of $1.93, exceeding the estimate of $1.76 by 9.74%.
Undervalued Relative to Earnings
The trailing Price-to-Earnings (P/E) ratio is 24.77, which is below the industry average and suggests the stock may be undervalued relative to its earnings potential.
Bearish Points (7)
High P/E Ratio vs. Industry
The P/E TTM (Trailing Twelve Months) of 24.77 is higher than some industry benchmarks, potentially indicating that the stock is trading at a premium, which could lead to a price correction if growth expectations are not met.
Slowing Revenue Growth
While revenue for FY2024 was $226.8 billion, the net margin has fluctuated, showing a recent dip to 0.4% in Q2 2024. This indicates potential margin pressure amidst significant revenue volumes.
Calendar
July 2025
1
Ex-Dividend Date
July 2025
15
Next Dividend Date
August 2025
12
Next Earnings Date
H: $2.07
A: $2.03
L: $1.96
H: 62.00B
A: 60.92B
L: 60.09B
Profile
Cardinal Health, Inc. operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution. It distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products, as well as medical supplies. The company also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; offers pharmacy management services to hospitals; operates pharmacies, including pharmacies in community health centers; and repackages generic pharmaceuticals and over-the-counter healthcare products. In addition, it manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe, and sharps disposals; compression solution, incontinence, nutritional delivery, and wound care products; single-use surgical drapes, gowns, and apparel products; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. Further, the company distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. Additionally, it manufactures, prepares, delivers, and distributes radiopharmaceuticals and related treatments; and optimizes direct shipments through integrated technology solutions. The company was incorporated in 1979 and is headquartered in Dublin, Ohio.
Seasonals
Price Target
176.41 USD
The 39 analysts offering 1 year price forecasts for CAH have a max estimate of 200.00 and a min estimate of 127.12.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 100
Direct and primary competitor in pharmaceutical and medical surgical distribution, serving similar customer bases globally.
Weight: 98
Major direct competitor in pharmaceutical distribution, particularly serving healthcare providers and pharmacies.
Weight: 85
One of the world's largest pharmaceutical manufacturers; CAH is a key distributor of its diverse drug portfolio.
Weight: 83
A diversified healthcare giant manufacturing pharmaceuticals, medical devices, and consumer health products, all of which CAH distributes or interacts with.